Immunization

Clinical trial results show the immunogenicity, tolerability, and safety of V116 compared to a pneumococcal 20-valent conjugate vaccine for adults who had not previously received a pneumococcal vaccine.

Fractional COVID-19 dosing resulted in fewer adverse effects and costs while producing similar immune responses compared to a full dose vaccine.

Prefilled diluent and vaccine syringes may be easily mixed up

Encourage patients to locate and safely store their immunization records

By strengthening the continent's health care infrastructure, promoting local vaccine production, and facilitating global collaborations, the grant represents an important milestone toward better health care for all Africans.

Although vaccination status and the severity of COVID-19 infection were not correlated, the timing of vaccine administration influenced whether patients had severe COVID-19 infection.

The finding indicates that a potential vaccine can trigger a permanent response in individuals living with HIV-1.

Regardless of which of these vaccines patients receive, as long as they receive them according to the prescribed schedules, they can protect themselves and their community against the COVID-19 virus.

According to the investigators, Streptococcus pneumoniae and non-typeable Haemophilus influenzae are dominant pathogens of otitis media after birth.

Serotype 19A is still the most prevalent serotype for pneumococcal disease, with study authors calling for additional studies to determine the full burden of invasive pneumococcal disease.

The vaccine provides treatment prevention for individuals that are high risk of exposure to the chikungunya virus.

Both newly approved shots possess activity against subvariant EG5.1, which represents an estimated 21.5% of currently circulating variants

Individuals that are younger in age, Black, have low levels of education, and low income were associated with a lower chance of getting the flu shot each year.

Oldest adults should be prioritized for vaccinations as they remain high risk for severe conditions if infected.

Arexvy shows efficacy in helping protect adults aged 50 to 59 years with an increased risk for respiratory syncytial virus lower respiratory tract disease.

RSV can create a problematic infection among children 12 months of age or younger, older adults, and in patients with immunocompromised conditions.

Penbraya (Pfizer Inc) is the first and only approved pentavalent vaccine that confers protection against the most common meningococcal serogroups—A, B, C, W-135, and Y, in individuals 10 through 25 years of age.

An overview of updated CDC ACIP recommendations for COVID-19 vaccines available through commercial channels for the 2023-2024 season.

In a recent study, approximately 99% of children who received solid organ transplant and live vaccination against rubella had antibodies 1 to 3 months post-vaccination.

Understanding the recommended ages for vaccination is crucial to properly advise patients and parents who have questions

Engaging technicians in immunizations has been crucial to public health

Investigators suggest that the Bacille Calmette–Guérin vaccine, which prevented tuberculosis in nonhuman primates infected with SIV, can also protect against HIV.

The clinical trial success in canines may have broader implications for applicability.

mRNA-1083 (Moderna) was found comparable to the standard dose of Fluarix (GSK) in adults aged 50 to 64 years and Fluzone HD ( Sanofi) for influenza and Spikevax (Moderna) for COVID-19.

NVX-CoV2601 vaccine adjuvanted 2023-2024 formula granted EUA for the prevention of COVID-19 in those 12 years of age and older.

Similarly, the results of a survey by the National Foundation for Infectious Diseases demonstrated that approximately 23% were worried about COVID-19 and 19% for respiratory syncytial virus.

Katalin Karikó, PhD, and Drew Weissman, MD, PhD, win Nobel Prize for discoveries in the area of nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.

Most patients had improved clinical response within 90 days of receiving the dendritic cell vaccine and ASCT.

With respiratory syncytial virus vaccine development for infants and children proceeding slowly, therapeutic developers have focused on passive immunity